Objective: To study the correlation of high-risk human papillomavirus 16 and 18 (HPV16/18) infections with the risk of prostate cancer (PCa) and their association with the clinicopathologic indexes of PCa.
Methods: We collected tissue samples from 75 cases of PCa and 73 cases of benign prostatic hyperplasia (BPH). We detected HPV16/18 infections in the samples by immunohistochemistry and PCR combined with reverse dot blot (RDB) assay.
Results: Immunohistochemistry revealed 16 cases of HPV16/18 positive in the PCa (21.3%) and 7 cases in the BPH samples (9.5%), with statistically significant difference between the two groups (P=0.049). PCR combined with RDB assay showed 17 cases of HPV16 infection (22.6%) and 13 cases of HPV18 infection (17.8%), including 4 cases of HPV16/18 positive, in the PCa group, remarkably higher than 6 cases of HPV16 infection (8.2%), 3 cases of HPV18 infection (4.1%) and no HPV16/18 positive in the BPH controls (P=0.001). No significant differences were observed between the result of immunohistochemistry and that of PCR combined with RDB assay (P=0.069). The risk of HPV16/18 infections was found to be correlated with the clinical T-stage and Gleason score of PCa (P<0.05 ) but not with the patient's age, PSA level or lymph node metastasis (P>0.05 ).
Conclusions: High-risk HPV16/18 infections are correlated with the risk of prostate cancer.
目的：通过检测高危型人乳头瘤病毒(HPV)16/18在前列腺癌(PCa)和良性前列腺增生(BPH)中的表达，探讨HPV16/18与PCa发病之间的相关性，并分析其与临床相关病理参数之间的关系。方法： 选取75例PCa和73例BPH组织标本，通过免疫组化和PCR结合反向斑点杂交（RDB）技术，检测HPV16/18的感染情况。 结果：免疫组化检测显示，75例PCa标本中16例HPV16/18阳性，阳性率为21.3%；73例BPH标本中7例阳性，阳性率为9.6%，两者比较差异有统计学意义（P=0.049）。PCR结合RDB技术检测显示，75例PCa标本中HPV16阳性17例（22.7%）、HPV18阳性13例（17.3%），其中有4例HPV16/18均阳性；73例BPH标本中HPV16阳性6例（8.2%），HPV18阳性3例（4.1%），无共同阳性例数，两者HPV16/18感染率比较差异有统计学意义（P=0.001）。对比免疫组化和PCR结合RDB 2种方法，两者比较无统计学差异（P=0.069）。HPV16/18感染与PCa临床病理参数中的临床T分期、Gleason评分、临床危险因素等级有一定相关性（P均<0.05），而与年龄、PSA值、有无淋巴结转移等参数无相关性。 结论： 高危型HPV16/18感染与PCa存在一定的相关性。.
Keywords: correlation; human papillomavirus 16/18; prostate cancer.